Symbols / CING
CING Chart
About
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials. It also develops CTx-2103 (buspirone) that is in a formulation stage for the treatment of anxiety and mental health disorders; and plans to initiate the clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD in children, adolescents, and adults. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 47.21M |
| Enterprise Value | 41.30M | Income | -21.39M | Sales | — |
| Book/sh | 0.58 | Cash/sh | 0.91 | Dividend Yield | — |
| Payout | 0.00% | Employees | 13 | IPO | — |
| P/E | — | Forward P/E | -4.50 | PEG | — |
| P/S | — | P/B | 10.91 | P/C | — |
| EV/EBITDA | -2.07 | EV/Sales | — | Quick Ratio | 1.05 |
| Current Ratio | 1.26 | Debt/Eq | 131.81 | LT Debt/Eq | — |
| EPS (ttm) | -2.77 | EPS next Y | -1.41 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-11-13 17:00 | ROA | -106.64% |
| ROE | -275.85% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 7.45M |
| Shs Float | 6.62M | Short Float | 5.33% | Short Ratio | 1.23 |
| Short Interest | — | 52W High | 7.92 | 52W Low | 3.20 |
| Beta | -0.75 | Avg Volume | 252.25K | Volume | 306.31K |
| Target Price | $27.77 | Recom | None | Prev Close | $6.09 |
| Price | $6.34 | Change | 4.11% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$27.77
Mean price target
2. Current target
$6.34
Latest analyst target
3. DCF / Fair value
$-25.21
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$6.34
Low
$8.00
High
$58.00
Mean
$27.77
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-12-08 | main | Ascendiant Capital | Buy → Buy | $58 |
| 2025-11-19 | main | Roth Capital | Buy → Buy | $16 |
| 2025-10-15 | main | Roth Capital | Buy → Buy | $17 |
| 2025-08-22 | main | Ascendiant Capital | Buy → Buy | $62 |
| 2025-05-27 | main | Ascendiant Capital | Buy → Buy | $61 |
| 2025-05-19 | main | Roth Capital | Buy → Buy | $11 |
| 2025-04-21 | main | Ascendiant Capital | Buy → Buy | $60 |
| 2025-03-06 | reit | HC Wainwright & Co. | Buy → Buy | $20 |
| 2025-01-30 | main | HC Wainwright & Co. | Buy → Buy | $20 |
| 2025-01-10 | init | Roth MKM | — → Buy | $12 |
| 2024-11-20 | up | Maxim Group | Hold → Buy | — |
| 2024-01-05 | main | HC Wainwright & Co. | Buy → Buy | $8 |
| 2023-12-22 | down | Laidlaw & Co. | Buy → Hold | — |
| 2023-12-19 | down | Maxim Group | Buy → Hold | — |
| 2023-12-18 | down | Maxim Group | Buy → Hold | — |
- Insider Purchase: SVP and CFO of $CING Buys 4,864 Shares - Quiver Quantitative Wed, 11 Feb 2026 08
- Ascendiant Capital Maintains Cingulate (CING) Buy Recommendation - Nasdaq Mon, 08 Dec 2025 08
- Cingulate Secures $12 Million PIPE to Advance CTx-1301 - The Globe and Mail Wed, 18 Feb 2026 08
- PDUFA May 31, 2026: Cingulate NDA Accepted for once-daily CTx-1301 in ADHD under 505(b)(2) - Stock Titan ue, 14 Oct 2025 07
- Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 3Q25 - TMX Newsfile ue, 18 Nov 2025 08
- Dow Futures Push Higher After Breaking 50,000: Why OPGN, ACHR, LI, HIMS, CING Are Trending Today - Stocktwits Sat, 07 Feb 2026 08
- Cingulate Signs Multiple Material Agreements - TradingView Wed, 28 Jan 2026 08
- Cingulate Secures Exclusive Manufacturing Partnership with - GlobeNewswire Wed, 17 Sep 2025 07
- Should you sell your Cingulate stock? - Cantech Letter Fri, 19 Sep 2025 07
- Alexander & Baldwin exec. VP Ching sells $14,621 in stock - Investing.com Wed, 10 Dec 2025 08
- Cingulate Inc Appoints New Executive Chairman Amid Changes - The Globe and Mail Fri, 29 Aug 2025 07
- New Analyst Forecast: $CING Given $58 Price Target - Quiver Quantitative Mon, 08 Dec 2025 08
- Cingulate Advances Capital Raise with Private Placement Financing - TipRanks Fri, 06 Feb 2026 08
- Cingulate Inc Reinstates Shane Schaffer as CEO - The Globe and Mail ue, 16 Dec 2025 08
- Cingulate Announces Private Placement and New Preferred Stock - TipRanks Wed, 28 Jan 2026 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 19455 | 149804 | — | Purchase at price 7.70 per share. | WERTH PETER J. | Director | — | 2026-02-06 00:00:00 | I |
| 1 | 6809 | 52429 | — | Purchase at price 7.70 per share. | SCHAFFER SHANE J. | Chief Executive Officer | — | 2026-02-06 00:00:00 | I |
| 2 | 4864 | 37453 | — | Purchase at price 7.70 per share. | CALLAHAN JENNIFER L. | Chief Financial Officer | — | 2026-02-06 00:00:00 | D |
| 3 | 1946 | 14984 | — | Purchase at price 7.70 per share. | BRAMS MATTHEW | Officer | — | 2026-02-06 00:00:00 | D |
| 4 | 202 | 841 | — | Sale at price 4.16 per share. | MYERS LAURIE | Chief Operating Officer | — | 2024-08-15 00:00:00 | D |
| 5 | 1036008 | 753 | — | Conversion of Exercise of derivative security at price 0.00 per share. | WERTH PETER J. | Director and Beneficial Owner of more than 10% of a Class of Security | — | 2024-04-11 00:00:00 | I |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -14.99M | -22.18M | -17.11M | -19.97M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -15.55M | -23.53M | -17.68M | -20.71M |
| ReconciledDepreciation | 653.09K | 582.92K | 394.01K | 708.32K |
| EBITDA | -14.99M | -22.18M | -17.11M | -19.97M |
| EBIT | -15.65M | -22.76M | -17.50M | -20.68M |
| NetInterestIncome | 99.24K | -775.76K | -174.51K | -30.59K |
| NormalizedIncome | -15.55M | -23.53M | -17.68M | -20.71M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -15.55M | -23.53M | -17.68M | -20.71M |
| TotalExpenses | 15.65M | 22.76M | 17.50M | 20.68M |
| RentExpenseSupplemental | 346.00K | 496.00K | 478.00K | 484.00K |
| TotalOperatingIncomeAsReported | -15.64M | -22.76M | -17.50M | -20.68M |
| DilutedAverageShares | 3.40M | 75.44K | 47.21K | 30.89K |
| BasicAverageShares | 3.40M | 75.44K | 47.21K | 30.89K |
| DilutedEPS | -4.57 | -311.99 | -374.40 | -669.60 |
| BasicEPS | -4.57 | -311.99 | -374.40 | -669.60 |
| DilutedNIAvailtoComStockholders | -15.55M | -23.53M | -17.68M | -20.71M |
| NetIncomeCommonStockholders | -15.55M | -23.53M | -17.68M | -20.71M |
| NetIncome | -15.55M | -23.53M | -17.68M | -20.71M |
| NetIncomeIncludingNoncontrollingInterests | -15.55M | -23.53M | -17.68M | -20.71M |
| NetIncomeContinuousOperations | -15.55M | -23.53M | -17.68M | -20.71M |
| TaxProvision | 0.00 | 0.00 | 0.00 | 0.00 |
| PretaxIncome | -15.55M | -23.53M | -17.68M | -20.71M |
| NetNonOperatingInterestIncomeExpense | 99.24K | -775.76K | -174.51K | -30.59K |
| TotalOtherFinanceCost | -99.24K | 775.76K | 174.51K | 30.59K |
| OperatingIncome | -15.65M | -22.76M | -17.50M | -20.68M |
| OperatingExpense | 15.65M | 22.76M | 17.50M | 20.68M |
| ResearchAndDevelopment | 9.45M | 15.49M | 9.00M | 8.41M |
| SellingGeneralAndAdministration | 6.20M | 7.27M | 8.51M | 12.27M |
| GeneralAndAdministrativeExpense | 6.20M | 7.27M | 8.51M | 12.27M |
| OtherGandA | 3.01M | 2.58M | 2.83M | 1.73M |
| InsuranceAndClaims | 984.00K | 1.54M | 2.61M | 325.00K |
| RentAndLandingFees | 346.00K | 496.00K | 478.00K | 484.00K |
| SalariesAndWages | 1.86M | 2.64M | 2.59M | 9.73M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 3.40M | 97.29K | 47.12K | 47.12K |
| ShareIssued | 3.40M | 97.29K | 47.12K | 47.12K |
| NetDebt | 2.95M | |||
| TotalDebt | 5.10M | 3.51M | 5.87M | 881.13K |
| TangibleBookValue | 7.46M | -6.87M | 3.88M | 20.84M |
| InvestedCapital | 12.42M | -3.87M | 8.88M | 20.84M |
| WorkingCapital | 7.69M | -9.65M | 856.85K | 17.71M |
| NetTangibleAssets | 7.46M | -6.87M | 3.88M | 20.84M |
| CapitalLeaseObligations | 135.09K | 510.24K | 866.04K | 881.13K |
| CommonStockEquity | 7.46M | -6.87M | 3.88M | 20.84M |
| TotalCapitalization | 9.89M | -6.87M | 3.88M | 20.84M |
| TotalEquityGrossMinorityInterest | 7.46M | -6.87M | 3.88M | 20.84M |
| StockholdersEquity | 7.46M | -6.87M | 3.88M | 20.84M |
| GainsLossesNotAffectingRetainedEarnings | 0.00 | 165.00 | ||
| OtherEquityAdjustments | 165.00 | |||
| RetainedEarnings | -108.49M | -92.94M | -69.41M | -51.73M |
| AdditionalPaidInCapital | 115.94M | 86.07M | 73.29M | 72.57M |
| CapitalStock | 340.00 | 10.00 | 61.00 | 1.13K |
| CommonStock | 340.00 | 10.00 | 61.00 | 1.13K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 7.41M | 10.36M | 7.52M | 2.04M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 2.44M | 135.10K | 510.24K | 866.04K |
| LongTermDebtAndCapitalLeaseObligation | 2.44M | 135.10K | 510.24K | 866.04K |
| LongTermCapitalLeaseObligation | 0.00 | 135.10K | 510.24K | 866.04K |
| LongTermDebt | 2.44M | |||
| CurrentLiabilities | 4.97M | 10.23M | 7.01M | 1.18M |
| OtherCurrentLiabilities | 339.75K | 295.60K | ||
| CurrentDebtAndCapitalLeaseObligation | 2.66M | 3.38M | 5.36M | 15.10K |
| CurrentCapitalLeaseObligation | 135.09K | 375.14K | 355.81K | 15.10K |
| CurrentDebt | 2.53M | 3.00M | 5.00M | |
| CurrentNotesPayable | 2.53M | 3.00M | 5.00M | 0.00 |
| PensionandOtherPostRetirementBenefitPlansCurrent | 355.48K | 593.02K | 175.62K | |
| PayablesAndAccruedExpenses | 1.95M | 6.26M | 1.48M | 865.99K |
| CurrentAccruedExpenses | 484.15K | 937.93K | 662.15K | 601.30K |
| InterestPayable | 15.09K | 290.00K | 292.34K | 0.00 |
| Payables | 1.47M | 5.32M | 819.22K | 264.69K |
| TotalTaxPayable | 200.00K | 120.57K | 56.86K | |
| AccountsPayable | 1.27M | 5.20M | 762.36K | 264.69K |
| TotalAssets | 14.86M | 3.49M | 11.41M | 22.89M |
| TotalNonCurrentAssets | 2.20M | 2.91M | 3.54M | 4.00M |
| NetPPE | 2.20M | 2.91M | 3.54M | 4.00M |
| AccumulatedDepreciation | -3.30M | -2.64M | -2.06M | -1.67M |
| GrossPPE | 5.50M | 5.56M | 5.60M | 5.67M |
| Leases | 474.46K | 471.50K | 471.50K | 471.50K |
| ConstructionInProgress | 375.28K | 207.98K | 1.74M | 1.64M |
| OtherProperties | 4.46M | 4.69M | 3.20M | 3.37M |
| MachineryFurnitureEquipment | 192.75K | 187.65K | 187.65K | 187.65K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 12.66M | 578.59K | 7.87M | 18.88M |
| OtherCurrentAssets | 54.87K | 20.70K | 20.70K | 1.70M |
| CurrentDeferredAssets | 0.00 | 178.78K | 100.34K | 0.00 |
| PrepaidAssets | 368.29K | 312.08K | 2.16M | 1.70M |
| Receivables | 26.32K | 14.62K | 234.43K | 690.25K |
| OtherReceivables | 26.32K | 14.62K | 234.43K | 690.25K |
| CashCashEquivalentsAndShortTermInvestments | 12.21M | 52.42K | 5.36M | 16.49M |
| OtherShortTermInvestments | 0.00 | 933.00 | ||
| CashAndCashEquivalents | 12.21M | 52.42K | 5.36M | 16.49M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -18.66M | -15.26M | -16.04M | -11.25M |
| RepaymentOfDebt | -17.06K | -16.05K | -15.09K | -936.59K |
| IssuanceOfDebt | 4.96M | 3.00M | 5.00M | 0.00 |
| IssuanceOfCapitalStock | 25.88M | 6.97M | 0.00 | 20.37M |
| CapitalExpenditure | -211.80K | -224.10K | -153.42K | -814.74K |
| InterestPaidSupplementalData | 6.29K | 19.42K | 19.00K | 114.72K |
| EndCashPosition | 12.21M | 52.42K | 5.36M | 16.49M |
| BeginningCashPosition | 52.42K | 5.36M | 16.49M | 1.20M |
| ChangesInCash | 12.16M | -5.30M | -11.14M | 15.30M |
| FinancingCashFlow | 30.82M | 9.95M | 4.90M | 26.54M |
| CashFlowFromContinuingFinancingActivities | 30.82M | 9.95M | 4.90M | 26.54M |
| NetOtherFinancingCharges | -85.92K | 7.10M | ||
| NetCommonStockIssuance | 25.88M | 6.97M | 0.00 | 20.37M |
| CommonStockIssuance | 25.88M | 6.97M | 0.00 | 20.37M |
| NetIssuancePaymentsOfDebt | 4.95M | 2.98M | 4.98M | -936.59K |
| NetShortTermDebtIssuance | 3.00M | 0.00 | -500.33K | |
| ShortTermDebtPayments | 0.00 | -500.33K | ||
| ShortTermDebtIssuance | 3.00M | 5.00M | 0.00 | |
| NetLongTermDebtIssuance | 4.95M | 2.98M | 4.98M | -436.26K |
| LongTermDebtPayments | -17.06K | -16.05K | -15.09K | -436.26K |
| LongTermDebtIssuance | 4.96M | 3.00M | 5.00M | 0.00 |
| InvestingCashFlow | -211.80K | -224.10K | -152.65K | -814.74K |
| CashFlowFromContinuingInvestingActivities | -211.80K | -224.10K | -152.65K | -814.74K |
| NetOtherInvestingChanges | -165.00 | |||
| NetInvestmentPurchaseAndSale | 0.00 | 933.00 | 0.00 | |
| SaleOfInvestment | 0.00 | 933.00 | 0.00 | |
| PurchaseOfInvestment | 0.00 | |||
| NetPPEPurchaseAndSale | -211.80K | -224.10K | -153.42K | -814.74K |
| PurchaseOfPPE | -211.80K | -224.10K | -153.42K | -814.74K |
| OperatingCashFlow | -18.45M | -15.03M | -15.88M | -10.43M |
| CashFlowFromContinuingOperatingActivities | -18.45M | -15.03M | -15.88M | -10.43M |
| ChangeInWorkingCapital | -4.55M | 7.10M | 598.62K | -3.21M |
| ChangeInOtherCurrentLiabilities | -358.09K | -339.75K | -295.60K | -191.13K |
| ChangeInOtherCurrentAssets | 267.89K | 263.74K | 227.98K | 100.12K |
| ChangeInPayablesAndAccruedExpense | -4.54M | 5.19M | 791.00K | -1.32M |
| ChangeInPrepaidAssets | 88.40K | 1.77M | -580.59K | -1.26M |
| ChangeInReceivables | -11.70K | 219.81K | 455.82K | -538.48K |
| StockBasedCompensation | 995.48K | 812.67K | 800.80K | 12.78M |
| DepreciationAmortizationDepletion | 653.09K | 582.92K | 394.01K | 708.32K |
| DepreciationAndAmortization | 653.09K | 582.92K | 394.01K | 708.32K |
| Depreciation | 653.09K | 582.92K | 394.01K | 708.32K |
| NetIncomeFromContinuingOperations | -15.55M | -23.53M | -17.68M | -20.71M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for CING
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|